Clinical data analytics technology innovator becomes newest member of Microsoft’s global program designed to help startups quickly build and scale.
SciMar ONE, a clinical data analytics technology company, announced it has been selected as the newest member of Microsoft for Startups to help scale its proprietary artificial intelligence (AI)-powered drug development platform, The Scientific Data Engine (SDE).
Microsoft for Startups is a global program dedicated to helping B2B startups successfully scale their companies. As a participant, SciMar will gain access to Microsoft’s technologies with a streamlined path to selling alongside Microsoft and its global partner ecosystem.
Recommended AI News: Pax8 and LogMeIn Join Forces to Offer Partners LastPass Single Sign-On and Password Management Capabilities
In collaboration with Microsoft, SciMar will increase the global pharmaceutical industry’s access to automated clinical data analytics. The SDE™, a drug development platform, expedites delivery of safe and effective innovations using AI while de-risking corporate investments with a $34.4 M savings for each drug in development.
“We are honored to be selected to partner with Microsoft for Startups,” said Donna Conroy, MS, SciMar founder and CEO. “Keeping pace with data is a challenge for pharma. Drug development teams spend up to 80% of time searching and organizing data, leaving only 20% of time utilizing data to strategically innovate. The SDE streamlines the vital but relentless task of collecting, sorting, and analyzing data, allowing drug development teams to focus on what they do best, develop innovative therapies.”
Recommended AI News: Fast Simon Announces Integration of InstantSearch+ Using Microsoft Dynamics 365 Commerce
In 2020, SciMar evolved the SDE to a cloud-based SaaS platform to help global pharma companies better utilize clinical data. The technology combines a knowledgebase and advanced project management tools aligned to drug development workflow.
“Microsoft is focused on innovative healthcare partners. We see SciMar speeding the time-consuming task of data analytics,” said Sally Frank, Worldwide Lead, Health & Life Sciences, Microsoft for Startups. “SciMar’s work will allow biopharma companies to bring therapies to market faster and safer. This is exactly the type of thinking we seek in companies participating in our startup program.”
Recommended AI News: Vigorate Digital Solutions Selects Pivotree for AWS Managed Services
Comments are closed.